Last C$1.66 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:24 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

covalon technologies ltd (COV) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/14 - C$2.98
52 Week Low
10/1/13 - C$0.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

covalon technologies ltd (COV) Related Businessweek News

No Related Businessweek News Found

covalon technologies ltd (COV) Details

Covalon Technologies, Ltd. researches, develops, and commercializes healthcare technologies. It operates in two segments, Advanced Wound Care and Specialized Medical Device Coatings. The company offers medical coating platforms, including CovaCoat that provides photochemical process for covalently linking coating molecules to various medical device surfaces; and SilverCoat, an antimicrobial silicone foley catheter. Its medical coatings are used in infection control, therapeutic delivery, and lubricity. The company also offers process and manufacturing equipment validation assistance and on-site training services; and professional services, including feasibility studies, product formulation, prototype testing, validation, and manufacturing. In addition, it provides advanced wound care products comprising ColActive Plus Ag, an advanced wound care dressing; CovaGen, a bio-active wound contact layer dressing; CovaStat, a bio-active absorbable hemostatic sponge; and CovaSorb, a bio-active absorbent foam replacement dressing. Further, the company offers antimicrobial silicone dressings under the IV Clear and SurgiClear names for the vascular access and surgical wound care markets. It sells its technologies and products to medical companies and distributors worldwide. Covalon Technologies, Ltd. is headquartered in Mississauga, Canada.

covalon technologies ltd (COV) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: C$300.0K
Co-Founder and Chief Science Officer
Total Annual Compensation: C$150.0K
Vice President of Operations
Total Annual Compensation: C$155.0K
Compensation as of Fiscal Year 2013.

covalon technologies ltd (COV) Key Developments

Covalon Technologies Ltd. Announces Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014

Covalon Technologies Ltd. announced earnings results for the third quarter and nine months ended June 30, 2014. For the three months ended June 30, 2014, revenue was $1,291,378, a 13% decrease over the same period of the prior year. Net loss for the quarter was $240,156 compared to net income of $238,826 during the same period of the prior year. For the nine months, revenue was $7,855,170, compared with $2,579,492 in the same nine month period of the prior year, a 205% increase. Net income was $3,311,473 or $0.22 per share fully diluted, compared with a loss of $1,114,475 or $0.12 per share in the same nine month period of the prior year.

Covalon Technologies Announces Election of Elinor Caplan and Ian Brindle to Board of Directors

Covalon Technologies Ltd. announced the election of Elinor Caplan and Dr. Ian Brindle to the company's Board of Directors at its annual shareholders meeting. Elinor Caplan is the Chief Executive Officer of Canada Strategies Inc. She served as former Health Minister and Chair of Management Board for the Province of Ontario and has served as Minister of Citizenship and Immigration as well as Minister of National Revenue in the Cabinet of former Prime Minister, Rt. Hon. Jean Chrétien. Ms. Caplan has served on numerous boards and advisory groups in Canada and internationally and is the co-author of the book, From Innovation to Transformation. Dr. Ian Brindle is the former Vice President of Research and Dean of Chemistry of Brock University. Dr. Brindle is a professor of Chemistry, holds a Chancellor's Chair in Research Excellence, is a fellow of the Royal Society of Chemistry (UK) and is author of more than 70 publications in analytical chemistry.

Covalon Technologies Ltd. Announces Earnings Results for the Second Quarter and Six Months Ended March 31, 2014

Covalon Technologies Ltd. announced earnings results for the second quarter and six months ended March 31, 2014. For the quarter, the company reported revenue for three months of $2,041,591, a 285% increase over the same period of the prior year. Net income for the quarter of $431,211 compared to a loss of $558,831 during the same period of the prior year. For the six months, the company reported revenue of $6,563,792 and net income of $3,551,630 or $0.38 per share ($0.19 per share fully diluted). This is a substantial increase over the financial performance in the first half of the prior year with revenue of $1,101,860 and a loss of $1,353,301 or $0.15 per share. Year to date, the net increase in revenue and profitability was primarily due to increases in advanced wound dressing sales and the initial payment of $3,500,000 by Molnlycke Health Care AB related to the licensing of two of Covalon's latest products, IV Clear and SurgiClear, which was announced on November 4, 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COV:CN C$1.66 CAD 0.00

COV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COV.
View Industry Companies

Industry Analysis


Industry Average

Valuation COV Industry Range
Price/Earnings 6.3x
Price/Sales 1.5x
Price/Book 2.2x
Price/Cash Flow 4.1x
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVALON TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at